Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Aegis Sciences Corporation

Aegis Sciences Corporation Announces Successful $170 Million Debt Refinancing to Support Continued Growth
From Aegis Sciences Corporation
Via Business Wire
Aegis Sciences Corporation Announces Updates for Novel Psychoactive Substances (NPS) Testing
From Aegis Sciences Corporation
Via Business Wire
Aegis Sciences Corporation Launches MedProtectCDM to Transform Medication Adherence and Safety Monitoring for Chronic Conditions
From Aegis Sciences Corporation
Via Business Wire
Aegis Sciences Corporation Launches Innovative Dashboard to Track Novel Psychoactive Substances Nationwide
From Aegis Sciences Corporation
Via Business Wire
Aegis Sciences Corporation Collaborates with The McNabb Center to Evaluate the Impact of Xylazine Exposure on Opioid Withdrawal
From Aegis Sciences Corporation
Via Business Wire
Aegis Sciences Corporation Announces Updates for NPS Testing
From Aegis Sciences Corporation
Via Business Wire
Aegis Sciences Corporation Announces Its Adoption of Self-Regulatory Standards for NPS Testing
From Aegis Sciences Corporation
Via Business Wire
Aegis Sciences Corporation Achieves HITRUST Risk-based, 2-year Certification Demonstrating the Highest Level of Information Protection Assurance
From Aegis Sciences Corporation
Via Business Wire
CORRECTING and REPLACING Aegis Sciences Corporation Announces Expanded Testing for Marijuana
From Aegis Sciences Corporation
Via Business Wire
Aegis Sciences Corporation Further Expands Testing for Novel Psychoactive Substances
From Aegis Sciences Corporation
Via Business Wire
Aegis Sciences Corporation Study Shows Widespread Distribution of Xylazine
From Aegis Sciences Corporation
Via Business Wire
Aegis Sciences Corporation Acquires HealthTrackRx’s Toxicology Business Unit
From Aegis Sciences Corporation
Via Business Wire
Aegis Sciences Corporation Provides Insights Into Early Detection Methods of COVID-19 Variants
From Aegis Sciences Corporation
Via Business Wire
Aegis Sciences Corporation Launches Key Opinion Leadership Series With First Panel on Designer Drugs
From Aegis Sciences Corporation
Via Business Wire
Aegis Sciences Corporation Now Performs Monkeypox Testing
From Aegis Sciences Corporation
Via Business Wire
Aegis Launches Infectious Disease Testing
From Aegis Sciences Corporation
Via Business Wire
Aegis Launches COVID-19 Testing Program for Schools
From Aegis Sciences Corporation
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.